Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survival.

J Immunother Cancer · 2021 · PMC8666898 · PMID 34893523

Europe PMC DOI

hedged sentence

0.0530

closest p · 1.1× alpha

0.0530

boldest claim

The sentences

did not reach statistical significancep=0.053so close (0.05 < p ≤ 0.1)

Additionally, TMB ( figure 5B ) was slightly higher in HER2-positive patients, although this trend did not reach statistical significance (p=0.053).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.